Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13229MR)

This product GTTS-WQ13229MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13229MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2292MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ157MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ6447MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ666MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ6852MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ6714MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ3492MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ323MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW